ACEA 1021: Flip or flop?

CNS Drug Reviews

Volumn 10, Issue 4, 2004, Pages 337-348

  Petty, Margaret A ^a   Weintraub, Philip M ^a   Maynard, Kenneth I ^a  

^a SANOFI   (France)

Author keywords

ACEA 1021; Cerebral ischemia; Glycine site antagonist; Neuroprotection; NMDA receptor; Pain

Indexed keywords

6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

AGITATION; AMNESIA; ATAXIA; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; COMPETITIVE INHIBITION; CONVULSION; DIZZINESS; DRUG ABUSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; GASTROINTESTINAL SYMPTOM; HUMAN; NAUSEA; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PAIN; REVIEW; SIDE EFFECT; SOMNOLENCE; STROKE; STRUCTURE ACTIVITY RELATION; SYNAPTIC TRANSMISSION; VOMITING;

EID: 12344283820     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2004.tb00031.x     Document Type: Review

References (75)

1. Albers GW, Clark WM, Atkinson RP, Madden K, Data JL, Whitehouse MJ, for the Licostinel Acute Stroke Study Group. Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke. Stroke 1999;30:508-513.
2. Auer RN. Structural neurotoxicologic investigation of the glycine antagonist 5-nitro-6,7-dichloroquinoxalinedione (ACEA 1021). Neurotoxicology 1997;18:53-62.
3. Baker AJ, Zornow MH, Scheller MS, et al. Changes in extracellular concentrations of glutamate, aspartate, glycine, dopamine, serotonin, and dopamine metabolites after transient global ischemia in the rabbit brain. J Neurochem 1991;57:1370-1379.
4. Balster RL, Mansbach RS, Shelton KL, et al. Behavioral pharmacology of two novel substituted quinoxalinedione glutamate antagonists. Behav Pharmacol 1995;6:577-589.
5. Baron BM, Harrison BL, Kehne JH, et al. Pharmacological characterization of MDL 105,519, an NMDA receptor glycine antagonist. Eur J Pharmacol 1997;323:181-192.
6. Barone FC, Feuerstein GZ, Whote RF. Brain cooling during transient focal ischemia provides complete neuroprotection. Neurosci Biobehav Rev 1997;21:31-44.
7. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984;43:1369-1374.
8. Bespalov AY, Dravolina OA, Zvartau EE, Beardsley PM, Balster RL. Effects of NMDA receptor antagonists on cocaine-conditioned motor activity in rats. Eur J Pharmacol 2000;390:303-311.
9. Boast C, Gerhardt S, Pastor G, Lehmann J, Etienne P, Liebman J. The N-methyl-D-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils. Brain Res 1988;442:345-348.
10. Boireau A, Monterrat C, Bordier F, Meunier M, Imperato A. Effects of RPR118723, a novel antagonist at the glycine site of the NMDA receptor, in vitro. Eur J Pharmacol 2000;401:131-135.
11. Brennan TJ, Zahn PK. Effect of intrathecal ACEA 1021 in a rat model for postoperative pain. J Pain 2000;1:279-284.
12. Cai SX, Kher SM, Zhou Z-L, et al. Structure-activity relationships of alkyl- and alkoxysubstituted 1,4-dihydroquinolaxaline-2,3-diones: Potent and systemically active antagonists for the glycine site of the NMDA receptor. J Med Chem 1997;40:730-738.
13. Carey RJ, Dai H, Krost M, Huston JP. The NMDA receptor and cocaine: Evidence that MK-801 can induce behavioral sensitization effects. Pharmacol Biochem Behav 1995;51:901-908.
14. Carter AJ. Many agents that antagonize the NMDA receptor-channel complex in vivo also cause disturbances of motor coordination. J Pharmacol Exp Ther 1994;269:573-580.
15. Dannhardt G, Kohl BK. The glycine site on the NMDA receptor: Structure-activity relationships and possible therapeutic applications. Curr Med Chem 1998;5:253-263.
16. Danysz W, Parsons CG, Karcz-Kubicha M, et al. Glycine B antagonists as potential therapeutic agents. Previous hopes and present reality. Amino Acids 1998;14:235-239.
17. 125I-MK-801 binding after subdural hematoma in the rat: An in vivo autoradiographic study. J Neurosurg 1996;85:655-661.
18. Dickenson AH, Aydar E. Antagonism at the glycine's site on the NMDA receptor reduces spinal nociception in the rat. Neurosci Lett 1991;121:263-266.
19. Fix AS, Long GG, Wozniak DF, Olney JW. Pathomorphologic effects of N-methyl-D-aspartate antagonists in the rat posterior cingulated/retrospinal cerebral cortex. A review. Drug Dev Res 1994;32:147-152.
20. Grotta J, Picone C, Ostrow P, et al. CGS-19755, a competitive NMDA receptor antagonist reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia. Ann Neurol 1990;27:612-619.
21. Hatfield RH, Gill R, Brazell C. The dose-response relationship and therapeutic window for dizocilpine (MK-801) in a rat focal ischaemia model. Eur J Pharmacol 1992;216:1-7.
22. Hawkinson JE, Huber KR, Sahota PS, Hsu, HH, Weber E, Whitehouse MJ. The N-methyl-D-aspartate (NMDA) receptor glycine site antagonist ACEA 1021 does not produce pathological changes in rat brain. Brain Res 1997;744:227-234.
23. Hicks CA, Ward MA, Ragumoorthy N, et al. Evaluation of glycine site antagonists of the NMDA receptor in global cerebral ischemia. Brain Res 1999;819:65-74.
24. Hoffman PL, NMDA receptors in alcoholism. Int Rev Neurobiol 2003;56:35-82
25. Ilyin VI, Whittemore ER, Tran M, et al. Pharmacology of ACEA 1416: A potent systemically active NMDA receptor glycine site antagonist. Eur J Pharmacol 1996;310:107-114.
26. Jimonet P, Ribeill Y, Bohme GA, et al. Indeno[1,2-b]pyrazin-2,3-diones: A new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem 2000;43:2371-2381.
27. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987;325:529-531.
28. Karler R, Calder LD, Chaudhry IA, Turkanis SA. Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. Life Sci 1989;45:599-606.
29. Keana JFW, Kher SM, Cai SM, et al. Synthesis and structure-activity relationships of substituted 1,4-dihydroquinoxaline-2,3-diones: Antagonism of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors. J Med Chem 1995;38:4367-4379.
30. Kemp JA, Leeson PD. The glycine site of the NMDA receptor - five years on. Trends Pharmacol Sci 1993;14:20-25.
31. Kretschmer BD, Kratzer U, Breithecker K, Koch M. ACEA 1021, a glycine site antagonist with minor psychotomimetic and amnestic effects in rats. Eur J Pharmacol 1997;331:109-116.
32. Krystal JH, D'Souza DC, Petrakis IL, et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 1999;7:125-143.
33. Kulagowski JJ, Baker R, Curtis NR, et al. 3′-(Arylmethyl- and 3′-aryloxy)-3-phenyl-4-hydroxyquinoline-2(1H)-ones: Orally active antagonists of the glycine site on the NMDA receptor. J Med Chem 1994;37:1402-1405.
34. Leeson PD, Iversen LL. The glycine site on the NMDA receptor: Structure-activity relationships and therapeutic potential. J Med Chem 1994;37:4053-4067.
35. Lester RA, Tong G, Jahr CE. Interactions between the glycine and glutamate binding sites of the NMDA receptor. J Neurosci 1993;13:1088-1096.
36. Lufty K, Weber E. Attenuation of nociceptive responses by ACEA 1021, a competitive NMDA receptor/glycine site antagonist, in the mice. Brain Res 1996;743:17-23.
37. Lutfy K, Shen KZ, Kwon IS, et al. Blockade of morphine tolerance by ACEA 1328, a novel NMDA receptor/glycine site antagonist. Eur J Pharmacol 1995;273:187-189.
38. Lutfy K, Shen KZ, Woodward RM, Weber E. Inhibition of morphine tolerance by NMDA receptor antagonists in the formalin test. Brain Res 1996;731:171-181.
39. Martin H, Warner DS, Todd MM. Effects of glycine receptor antagonism on spreading depression in the rat. Neurosci Lett 1994;180:285-289.
40. Matsumoto RR, Nguyen D, Truong DD. Strychnine-insensitive glycine site antagonists attenuate a cardiac arrest-induced movement disorder. Eur J Pharmacol 1995;275:117-123.
41. Matsumoto RR, Brackett RL, Kanthasamy AG. Novel NMDA/glycine site antagonists attenuate cocaine-induced behavioral toxicity. Eur J Pharmacol 1997;338:233-242.
42. McFarlane C, Warner DS, Nader A, Dexter F. Glycine receptor antagonism. Effects of ACEA 1021 on the minimum alveolar concentration for halothane in the rat. Anesthesiology 1995;82:963-968.
43. Millan MJ, Seguin L. Chemically-diverse ligands at the glycine B site coupled to N-methyl-D-aspartate (NMDA) receptors selectively block the late phase of formalin-induced pain in mice. Neurosci Lett 1994;178:139-143.
44. Morikawa E, Ginsberg MD, Dietrich WD, et al. The significance of brain temperature in focal cerebral ischemia: Histopathological consequences of middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 1992;12:380-389.
45. Muir KW, Grosset DG, Gamzu E, Lees KR. Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br J Clin Pharmacol 1994;38:33-38.
46. Nagata R, Tanno N, Kodo T, et al. Tricyclic Quinoxalinones: 5,6-dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-diones as potent antagonists for the glycine binding site of the NMDA receptor. J Med Chem 1994;37:3956-3968.
47. Nasstrom J, Karlsson U, Post C. Antinociceptive actions of different classes of excitatory amino acid receptor antagonists in mice. Eur J Pharmacol 1992;212:21-29.
48. Newell DW, Barth A, Malouf AT. Glycine site NMDA receptor antagonists provide protection against ischemia-induced neuronal damage in hippocampal slice cultures. Brain Res 1995;675:38-44.
49. Nishiyama T. Interaction between intrathecal morphine and glutamate receptor antagonists in formalin test. Eur J Pharmacol 2000;395:203-210.
50. Nishizawa Y. Glutamate release and neuronal damage in ischemia. Life Sci 2001;69:369-381.
51. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989;244:1360-1362.
52. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: Mechanism and prevention. Science 1991;254:1515-1518.
53. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J. Focal cerebral ischaemia in the cat: Treatment with the glutamate antagonist MK-801 after induction of ischaemia. J Cereb Blood Flow Metab 1988;8:757-762.
54. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann Neurol 1988;24:543-551.
55. Park CK, McCulloch J, Kang JK, Choi CR. Efficacy of D-CP-Pene, a competitive N-methyl D-aspartate antagonist in focal cerebral ischemia in the rat. Neurosci Lett 1992;147:41-44.
56. Parsons CG, Danysz W, Hesselink M, et al. Modulation of NMDA receptors by glycine - introduction to some basic aspects and recent developments. Amino Acids 1998;14:207-216.
57. Petty MA, Neumann-Haefelin C, Kalish J, Sarhan S, Wettstein JG, Juretschke HP. In vivo neuroprotective effects of ACEA 1021 confirmed by magnetic resonance imaging in ischemic stroke. Eur J Pharmacol 2003;474:53-62.
58. Raigorodsky G, Urea G. Involvement of N-methyl-D-aspartate receptors in nociception and motor control in the spinal cord of the mouse: Behavioral, pharmacological and electrophysiological evidence. Neuroscience 1990;36:601-610.
59. Ramirez E, Matsumoto RR, Brackett R, Kanthasamay AG. Novel N-methyl-D-aspartate (NMDA)/glycine site antagonists block cocaine-induced toxicity and behavioural sensitization. Soc Neurosci Abstr 1997;23:260.
60. Sarhan S, Wettstein JG, Maynard KI. Delayed treatment with 5-nitro-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione, a glycine site N-methyl-D-aspartate antagonist, protects against permanent middle cerebral artery occlusion in male rats. Neurosci Lett 2003;347:147-150.
61. Scatton B. The NMDA receptor complex. Fundam Clin Pharmacol 1993;7:389-400.
62. Takaoka S, Bart RD, Pearlstein R, Brinkhous A, Warmer DS. Neuroprotective effect of NMDA receptor glycine recognition site antagonist persists when brain temperature is controlled. J Cereb Blood Flow Metab 1997;17:161-167.
63. Tran M, Lufty K, Xu Z, Cai SX, Weber E. Anticonvulsant structure-activity relationships of a series of novel NMDA receptor/glycine site antagonists in the maximal electroshock seizure (MES) model in mice. Soc Neurosci Abstr. 1995;21;Abstract 84.18.
64. Trist DG. Excitatory amino acid agonists and antagonists: Pharmacology and therapeutic applications. Pharm Acta Helv 2000;74:221-229.
65. Tsuchida E, Bullock R. The effect of the glycine site-specific N-methyl-D-aspartate antagonist ACEA1021 on ischemic brain damage caused by acute subdural hematoma in the rat. J Neurotrauma 1995;12:279-288.
66. Wallis RA, Panizzon KL. Glycine reversal of felbamate hypoxic protection. NeuroReport 1993;4:951-954.
67. Warner DS, Martin HJ, Ludwig P, McAllister A, Keana JFW, Weber E. In vivo models of cerebral ischemia: Effects of parentally administered NMDA receptor glycine site antagonists. J Cereb Blood Flow Metab 1995;15:188-196.
68. Whitehouse MJ, Navalta L, Densel M, et al. Initial clinical experience with ACEA 1021: Safety, tolerance and pharmacokinetics in healthy volunteers. J Stroke Cerebrovasc Dis 1997;6:151 (Abstract).
69. Wilding TJ, Huettner JE, Antagonist pharmacology of kainate- and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors. Mol Pharmacol 1996;49:540-546.
70. Wood ER, Bussey TJ, Phillips AG. A glycine antagonist reduces ischemia-induced CA1 cell loss in vivo. Neurosci Lett 1992;145:10-14.
71. Wood ER, Bussey TJ, Phillips AG. A glycine antagonist 7-chlorokynurenic acid attenuates ischemia-induced learning deficits. NeuroReport 1993;4:151-154
72. Woodward R, Huettner J, Guastella J, Keana J, Weber E. In vitro pharmacology of ACEA 1021 and ACEA 1031: Systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol Pharmacol 1995;47:568-581.
73. Woodward RM, Huettner JE, Tran M, Guastella J, Keanna JFW, Weber E. Pharmacology of 5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione: A novel systemically active ionotropic glutamate receptor antagonist. J Pharmacol Exp Ther 1995;275:1209-1218.
74. Yaksh TL. The spinal pharmacology of facilitation of afferent processing evoked by high-threshold afferent input of the postinjury pain state. Curr Opin Neurol Neurosurg 1993;6:250-256.
75. Zhou Z-L, Kher SM, Cai SX, et al. Synthesis and SAR of novel di and tri-substituted 1,4-dihydroquinoxaline-2,3-diones related to licostinel (ACEA 1021) as NMDA/glycine site antagonists. Bioorg Med Chem 2003;11:1760-1780.